2020 Annual Business Report

Our capital strategy

Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.

Our capital strategy

Our Financials & Outlook

  • In early 2020, the Company announced an $85 million debt financing transaction with leading U.S. healthcare funds Deerfield Management Company and OrbiMed Advisors.
  • In December 2020, Valneva shareholders approved EGM resolutions to support a potential US IPO.